Organoids for Preclinical Disease Modeling and Personalized Medicine
151,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
76 °P sammeln
  • Gebundenes Buch

Organoid technologies are preclinical models in which drug responses or radiotherapies are determined very closely to patient response. While until the recent past there were no three-dimensional systems in which the entire cellular content of an organ could be reflected, we can now create the physiological and structural features of an organ in vitro and model a disease effectively. As these diseases may be developmental defects, chronic diseases can also be investigated in detail at the gene and protein level with these systems. In terms of developmental biology, thanks to the use of…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Organoid technologies are preclinical models in which drug responses or radiotherapies are determined very closely to patient response. While until the recent past there were no three-dimensional systems in which the entire cellular content of an organ could be reflected, we can now create the physiological and structural features of an organ in vitro and model a disease effectively. As these diseases may be developmental defects, chronic diseases can also be investigated in detail at the gene and protein level with these systems. In terms of developmental biology, thanks to the use of organoids, it is possible to learn the physiological internal dynamics of organs and to model diseases other than cancer. Chapters include introductions to their respective topics, recent advancements and how future applications can be implemented to organoid models. Organoids for Preclinical Disease Modeling and Personalized Medicine serves as an aid to researchers working in this vital area of research.
Autorenporträt
Özge¿Sezin Somuncu is the Organoid Center Director and Senior Scientist in the Department of Radiation Oncology at DanäFarber Cancer Institute. Her research focuses on cancer biology, with special expertise in patient¿derived organoids, DNA damage and repair mechanisms (notably replication stress, USP1 and PARG pathways), and precision oncology. She earned her PhD from Yeditepe University and has held academic positions including Assistant Professor at Bahçe¿ehir University. Her recent work has concentrated on identifying functional biomarkers for drug sensitivity in ovarian cancer models. She has authored numerous peer¿reviewed publications, contributed to patent applications, and currently leads collaborative translational projects aimed at improving therapeutic strategies. She currently leads and supports organoid-based translational research, oversees collaborative studies between lab researchers and clinicians and helps integrate organoids into preclinical drug development pipelines.